Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Income from Continuing Operations (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Income from Continuing Operations for 13 consecutive years, with 60968000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 96.03% to 60968000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 105835000.0 through Dec 2025, up 1181.05% year-over-year, with the annual reading at 105847000.0 for FY2025, 1181.17% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 60968000.0 at Theravance Biopharma, up from 3611000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 60968000.0 in Q4 2025, with the low at 79679000.0 in Q1 2021.
  • Average Income from Continuing Operations over 5 years is 14886600.0, with a median of 14886000.0 recorded in 2022.
  • Peak annual rise in Income from Continuing Operations hit 465.46% in 2024, while the deepest fall reached 41.88% in 2024.
  • Over 5 years, Income from Continuing Operations stood at 57766000.0 in 2021, then soared by 75.32% to 14256000.0 in 2022, then skyrocketed by 40.31% to 8510000.0 in 2023, then soared by 465.46% to 31101000.0 in 2024, then soared by 96.03% to 60968000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 60968000.0, 3611000.0, and 54835000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.